We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VMI:NYSEValmont Industries, Inc. Analysis

Data as of 2026-05-09 - not real-time

$510.55

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Valmont Industries delivered a Q1 2026 earnings beat, posting revenue growth of 6.2% year‑over‑year to $1.03 billion and an EPS of $5.51 versus the consensus estimate of $4.72. The stock is trading at $510.55, just below the 52‑week high of $528.49 and comfortably above the 20‑, 50‑ and 200‑day moving averages, while the MACD remains bullish and the RSI sits at 67.5, indicating momentum but approaching overbought levels. Volume is trending lower, which could temper short‑term upside despite the strong technical backdrop.
Valuation metrics paint a mixed picture: the trailing P/E of 28.4 is slightly below the industry average of 29.9, and the forward P/E of 20.1 suggests earnings acceleration, yet the DCF‑derived fair value of $127.84 implies the market price is substantially overvalued with only a 3.2% upside potential. The dividend yield is modest at 0.57% with a low payout ratio of 15.6%, supporting sustainability, while a debt‑to‑equity of 55% and a beta of 1.24 signal moderate financial leverage and higher market sensitivity. Overall, the company benefits from solid revenue growth, strong cash generation, and a favorable industry backdrop, but the current premium pricing and elevated volatility warrant a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings beat and strong revenue growth
  • Technical bullishness but RSI near overbought and decreasing volume
  • Valuation gap between market price and DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings expansion reflected in a forward P/E of 20.1
  • Sustainable dividend with low payout ratio
  • Continued demand in infrastructure and agriculture segments

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Stable cash flow and solid ROE (~22%)
  • Elevated valuation relative to DCF estimates
  • Moderate leverage and higher beta indicating market sensitivity

Key Metrics & Analysis

Financial Health

Revenue Growth6.20%
Profit Margin8.91%
P/E Ratio28.4
ROE22.19%
ROA10.08%
Debt/Equity54.96
P/B Ratio6.1
Op. Cash Flow$494.8M
Free Cash Flow$187.2M
Industry P/E29.9

Technical Analysis

TrendBullish
RSI67.6
Support$394.46
Resistance$528.49
MA 20$474.49
MA 50$439.64
MA 200$414.67
MACDBullish
VolumeDecreasing
Fear & Greed Index90.73

Valuation

Fair Value$127.84
Target Price$527.00
Upside/Downside3.22%
GradeOvervalued
TypeGrowth
Dividend Yield0.57%

Risk Assessment

Beta1.24
Volatility46.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.